Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed

Journal of Inherited Metabolic Disease

Volumn 31, Issue 4, 2008, Pages 473-480

  Al Sawaf, S ^a   Mayatepek, E ^a   Hoffmann, B ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; HEPARAN SULFATE; IDURONATE 2 SULFATASE;

AIRWAY OBSTRUCTION; BODY BUILD; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CAUSE OF DEATH; CERVICAL MYELOPATHY; CHILD; COARSE FACE; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FOREHEAD; GASTROINTESTINAL DISEASE; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; HUNTER SYNDROME; HYDROCEPHALUS; LIFE EXPECTANCY; LYSOSOME STORAGE DISEASE; MENTAL DEFICIENCY; MOUTH DISEASE; NERVE COMPRESSION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROLOGICAL COMPLICATION; ONSET AGE; OPTIC NERVE; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SKIN DISEASE; SLEEP APNEA SYNDROME; SPINAL CORD COMPRESSION; SYMPTOM; THERAPY EFFECT; TONGUE SWELLING; X CHROMOSOME LINKAGE;

CARPAL TUNNEL SYNDROME; CEREBRAL INFARCTION; EYE DISEASES; GLYCOPROTEINS; HEARING LOSS; HUMANS; HYDROCEPHALUS; MENTAL RETARDATION; MUCOPOLYSACCHARIDOSIS II; NERVOUS SYSTEM DISEASES; SEIZURES; SLEEP APNEA SYNDROMES; SPINAL CORD COMPRESSION;

EID: 50149108962     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0878-x     Document Type: Review

References (67)

1. Abraham FA, Yatziv S, Russell A, Auerbach E (1974) Electrophysiological and psychophysical findings in Hunter syndrome. Arch Ophthalmol 91: 181-186.
2. Altarescu G, Chicco G, Whybra C, et al (2008) Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis 31: 117-123.
3. Altarescu G, Hill S, Wiggs E, et al (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 138: 539-547.
4. Altarescu G, Zimran A, Michelakakis H, Elstein D (2005) TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 31: 149-152.
5. Alves S, Mangas M, Prata MJ, et al (2006) Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations. J Inherit Metab Dis 29: 743-754.
6. Ballenger CE, Swift TR, Leshner RT, El Gammal TA, McDonald TF (1980) Myelopathy in mucopolysaccharidosis type II (Hunter syndrome). Ann Neurol 7: 382-385.
7. Banna M, Hollenberg R (1987) Compressive meningeal hypertrophy in mucopolysaccharidosis. AJNR Am J Neuroradiol 8: 385-386.
8. Beck M (1983) Papilloedema in association with Hunter's syndrome. Br J Ophthalmol 67: 174-177.
9. Capablo JL, Franco R, de Cabezon AS, Alfonso P, Pocovi M, Giraldo P (2007) Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia 48: 1406-1408.
10. Collins ML, Traboulsi EI, Maumenee IH (1990) Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 97: 1445-1449.
11. Dekaban AS, Constantopoulos G (1977) Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain. Acta Neuropathol (Berl) 39: 1-7.
12. Dickson P, McEntee M, Vogler C, et al (2007) Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 91: 61-68.
13. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE (2006) Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 95: 312-317.
14. Fisher RC, Horner RL, Wood VE (1974) The hand in mucopolysaccharide disorders. Clin Orthop Relat Res 191-199.
15. Fowler GW, Sukoff M, Hamilton A, Williams JP (1975) Communicating hydrocephalus in children with genetic inborn errors of metabolism. Childs Brain 1: 251-254.
16. Froissart R, Blond JL, Maire I, et al (1993) Hunter syndrome: Gene deletions and rearrangements. Hum Mutat 2: 138-140.
17. Gills JP, Hobson R, Hanley WB, McKusick VA (1965) Electroretinography and fundus oculi findings in Hurler's disease and allied mucopolysaccharidoses. Arch Ophthalmol 74: 596-603.
18. Goldberg MF, Duke JR (1967) Ocular histopathology in Hunter's syndrome. Systemic mucopolysaccharidosis type II. Arch Ophthalmol 77: 503-512.
19. Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 105: 2616-2621.
20. Hayes E, Babin R, Platz C (1980) The otologic manifestations of mucopolysaccharidoses. Am J Otol 2: 65-69.
21. Hill CM, Hogan AM, Onugha N, et al (2006) Increased cerebral blood flow velocity in children with mild sleep-disordered breathing: A possible association with abnormal neuropsychological function. Pediatrics 118: e1100-e1108.
22. Hoffmann B, Schwahn B, Knobbe CB, et al (2006) Acute neuronopathic Gaucher disease complicated by fatal gastrointestinal bleeding. Neuropediatrics 37: 163-165.
23. Hunter C (1917) A rare disease in two brothers. R Soc Med 10, 104-116.
24. Jones MZ, Alroy J, Rutledge JC, et al (1997) Human mucopolysaccharidosis IIID: Clinical, biochemical, morphological and immunohistochemical characteristics. J Neuropathol Exp Neurol 56: 1158-1167.
25. Kakkis E, McEntee M, Vogler C, et al (2004) Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83: 163-174.
26. Karpati G, Carpenter S, Eisen AA, Wolfe LS, Feindel W (1974) Multiple peripheral nerve entrapments. An unusual phenotypical variant of the Hunter syndrome (mucopolysaccharidosis II) in a family. Arch Neurol 31: 418-422.
27. Kato T, Kato Z, Kuratsubo I, et al (2007) Evaluation of ADL in patients with Hunter disease using FIM score. Brain Dev 29: 298-305.
28. Kenyon KR (1976) Ocular manifestations and pathology of systemic mucopolysaccharidoses. Birth Defects Orig Artic Ser 12: 133-153.
29. Kurihara M, Kumagai K, Goto K, Imai M, Yagishita S (1992) Severe type Hunter's syndrome. Polysomnographic and neuropathological study. Neuropediatrics 23: 248-256.
30. Lee C, Dineen TE, Brack M, Kirsch JE, Runge VM (1993) The mucopolysaccharidoses: Characterization by cranial MR imaging. AJNR Am J Neuroradiol 14: 1285-1292.
31. MacDougal B, Weeks PM, Wray RC Jr (1977) Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases. Plast Reconstr Surg 59: 260-263.
32. Matheus MG, Castillo M, Smith JK, Armao D, Towle D, Muenzer J (2004) Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 46: 666-672.
33. Muenzer J, Wraith JE, Beck M, et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8: 465-473.
34. Narita AS, Russell-Eggitt I (1996) Bilateral epiretinal membranes: A new finding in Hunter syndrome. Ophthalm Genet 17: 75-78.
35. Neely J, Carpenter J, Hsu W, Jordan L, Restrepo L (2006) Cerebral infarction in Hunter syndrome. J Clin Neurosci 13: 1054-1057.
36. Neufeld EF, Liebaers I, Epstein CJ, Yatziv S, Milunsky A, Migeon BR (1977) The Hunter syndrome in females: Is there an autosomal recessive form of iduronate sulfatase deficiency? Am J Hum Genet 29: 455-461.
37. Neufeld E and Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3421-3454
38. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A 100: 1902-1907.
39. Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ (2007) Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 90: 49-57.
40. Papsin BC, Vellodi A, Bailey CM, Ratcliffe PC, Leighton SE (1998) Otologic and laryngologic manifestations of mucopolysaccharidoses after bone marrow transplantation. Otolaryngol Head Neck Surg 118: 30-36.
41. Parsons VJ, Hughes DG, Wraith JE (1996) Magnetic resonance imaging of the brain, neck and cervical spine in mild Hunter's syndrome (mucopolysaccharidoses type II). Clin Radiol 51: 719-723.
42. Patil SP, Schneider H, Schwartz AR, Smith PL (2007) Adult obstructive sleep apnea: Pathophysiology and diagnosis. Chest 132: 325-337.
43. Pitz S, Ogun O, Bajbouj M, Arash L, Schulze-Frenking G, Beck M (2007) Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: A 4-year experience. Arch Ophthalmol 125: 1353-1356.
44. Sakakihara Y, Imabayashi T, Suzuki Y, Kamoshita S (1994) Elevated levels of dolichol in the brains of mucopolysaccharidosis and related disorders. Mol Chem Neuropathol 22: 97-103.
45. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: A therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99: 15428-15433.
46. Schwartz IV, Ribeiro MG, Mota JG, et al (2007) A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 96: 63-70.
47. Shapiro J, Strome M, Crocker AC (1985) Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94: 458-461.
48. Takahashi Y, Sukegawa K, Aoki M, et al (2001) Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation. Pediatr Res 49: 349-355.
49. Tokic V, Barisic I, Huzjak N, Petkovic G, Fumic K, Paschke E (2007) Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr 166: 727-732.
50. Topping TM, Kenyon KR, Goldberg MF, Maumenee AE (1971) Ultrastructural ocular pathology of Hunter's syndrome. Systemic mucopolysaccharidosis type II. Arch Ophthalmol 86: 164-177.
51. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 279: 13478-13487.
52. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA (2005) Mucopolysaccharidosis type II in females: Case report and review of literature. Pediatr Neurol 32: 270-272.
53. Urayama A, Grubb JH, Banks WA, Sly WS (2007) Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc Natl Acad Sci U S A 104: 12873-12878.
54. Van Aerde J, Campbell A (1983) Hydrocephalus and shunt placement. Am J Dis Child 137: 187-188.
55. Van Aerde J, Plets C, Van der Hauwaert L (1981) Hydrocephalus in Hunter syndrome. Acta Paediatr Belg 34: 93-96.
56. Vedolin L, Schwartz IV, Komlos M, et al (2007a) Brain MRI in mucopolysaccharidosis: Effect of aging and correlation with biochemical findings. Neurology 69: 917-924.
57. Vedolin L, Schwartz IV, Komlos M, et al (2007b) Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. AJNR Am J Neuroradiol 28: 1029-1033.
58. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22: 638-648.
59. Villani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez YR, Di Natale P (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res 85: 612-622.
60. Vogler C, Levy B, Grubb JH, et al (2005) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 102: 14777-14782.
61. Wolf D (1942) Microscopic study of temporal bones in dysostosis multiplex (gargoylism). Laryngoscope 52: 218-223.
62. Wraith JE, Beck M, Lane R, et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L -iduronidase (laronidase). Pediatrics 120: E37-e46 [Epub 2007 Jun 4].
63. Wraith JE, Cooper A, Thornley M, et al (1991) The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II-Hunter syndrome). Hum Genet 87: 205-206.
64. Yatziv S, Epstein CJ (1977) Hunter syndrome presenting as macrocephaly and hydrocephalus. J Med Genet 14: 445-447.
65. Young ID, Harper PS (1982) Mild form of Hunter's syndrome: Clinical delineation based on 31 cases. Arch Dis Child 57: 828-836.
66. Young ID, Harper PS (1983) The natural history of the severe form of Hunter's syndrome: A study based on 52 cases. Dev Med Child Neurol 25: 481-489.
67. Yuen A, Dowling G, Johnstone B, Kornberg A, Coombs C (2007) Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol 22: 260-263.